文献速递白血病

接受强化化疗的急性髓系白血病患者中NFYA剪接变体的临床相关性

Clinical relevance of NFYA splice variants in patients with acute myeloid leukaemia undergoing intensive chemotherapy.
PubMed 文献 · Br J Haematol · 2024-08-28

该研究用RNA-seq分析341例急性髓系白血病患者白血病细胞的异常剪接,与健康CD34+造血干细胞比较,发现NFYA基因存在NFYA-L和NFYA-S两种主要异构体。NFYA-S优势组经强化化疗后特征更有利、结局更好,且不依赖年龄和欧洲白血病网风险分类;NFYA-L优势组相对化疗耐药,NFYA-S过表达可增加阿糖胞苷敏感性。

要点

  • NFYA-S优势组经强化化疗后特征更有利、结局更好,不依赖年龄和欧洲白血病网风险分类。
  • NFYA-L优势组(如KMT2A重排白血病中所见)与相对化疗耐药相关。
  • OCI-AML3细胞中过表达NFYA-S促进增殖、S期进入并增加阿糖胞苷敏感性。

核心结论

  • NFYA异常剪接是急性髓系白血病潜在的预后生物标志物。

研究设计与样本

  • 用RNA-seq分析341例急性髓系白血病患者白血病细胞的异常剪接,并与健康CD34+造血干细胞比较。

主要发现

  • NFYA基因存在NFYA-L(长)和NFYA-S(短)两种主要异构体,差异在于外显子3是否包含。
  • NFYA-S优势组(NFYA-L较低而NFYA-S较高)经强化化疗后特征更有利、结局更好,不依赖年龄和欧洲白血病网风险分类。
  • NFYA-L优势组(NFYA-L较高而NFYA-S较低)相对化疗耐药,如KMT2A重排白血病中所见。
  • NFYA-S优势病例转录组显示细胞周期基因上调,类似活跃造血干细胞,显示相对化疗敏感。
  • OCI-AML3细胞中过表达NFYA-S促进细胞增殖、S期进入并增加阿糖胞苷敏感性。

关键数值与推荐

  • 预后效应在癌症基因组图谱队列中得到验证。

临床怎么用

  • 作者认为NFYA异常剪接是急性髓系白血病潜在的预后生物标志物,NFYA-S过表达提示其临床和治疗相关性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Aberrant alternative splicing (AS) contributes to leukemogenesis, but reports on the clinical and biological implications of aberrant AS in acute myeloid leukaemia (AML) remain limited. Here, we used RNA-seq to analyse AS in AML cells from 341 patients, comparing them to healthy CD34+ haematopoietic stem cells (HSCs). Our findings highlight distinct AS patterns in the nuclear transcription factor Y subunit alpha (NFYA) gene, with two main isoforms: NFYA-L (Long) and NFYA-S (Short), differing in exon 3 inclusion. Patients with lower NFYA-L but higher NFYA-S expression, termed NFYA-S predominance, displayed more favourable characteristics and better outcomes following intensive chemotherapy, regardless of age and European LeukemiaNet risk classification, compared to those with higher NFYA-L but lower NFYA-S expression, termed NFYA-L predominance. The prognostic effects were validated using The Cancer Genome Atlas cohort. Transcriptome analysis revealed upregulated cell cycle genes in NFYA-S predominant cases, resembling those of active HSCs, demonstrating relative chemosensitivity. Conversely, NFYA-L predominant cases, as observed in KMT2A-rearranged leukaemia, were associated with relative chemoresistance. NFYA-S overexpression in OCI-AML3 cells promoted cell proliferation, S-phase entry and increased cytarabine sensitivity, suggesting its clinical and therapeutic relevance in AML. Our study underscores NFYA AS as a potential prognostic biomarker in AML.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Yang YT, Yao CY, Kao CJ, et al. Clinical relevance of NFYA splice variants in patients with acute myeloid leukaemia undergoing intensive chemotherapy. Br J Haematol. 2024. PMID: 39192759. doi:10.1111/bjh.19733

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。